AI Tools Speed Drug Candidate Screening for Pharma

Boltz's $110 million raise funds growth of pay-per-use molecule and protein design models already used by six of the 20 largest drugmakers.

Updated on Nov. 20, 2026 in Startups

Bold flat-color editorial illustration of a row of amber-filled glass vials in a steel rack against a navy field, evoking AI-driven drug candidate screening.
Boltz PBC raised $110 million in a Series A round led by Bessemer to expand AI models that six of the 20 largest drugmakers already pay to use. AI Illustration. Upload story photo >

Live Poll

Do you think AI will make new medicines faster and cheaper for ordinary people?

Boltz PBC, which develops artificial intelligence models for pharmaceutical researchers, announced a $110 million Series A funding round led by Bessemer. The company's models, BoltzMol-1 and BoltzProt-1, are commercially sold through an application programming interface and are in use, so the products shipped rather than remain at research stage.

Why it matters

Drug discovery typically involves reviewing hundreds of thousands of candidate molecules over months at a cost of millions of dollars, and the funding aims to speed that process with AI. The round signals investor confidence in AI tools as commercial infrastructure for pharmaceutical research.

BoltzMol-1 generates binding affinity data by reviewing only a few dozen promising molecules, and it found small molecule hits for six of 10 challenging targets tested. BoltzProt-1 generates tens of thousands of protein designs from that hit data, but the company has not reported independent benchmarks for either model.

The players

Boltz PBC

An AI company building molecule and protein design models for pharmaceutical researchers, with six of the world's 20 largest pharmaceutical companies counted as clients.

Bessemer

A venture capital firm that led the Series A investment in Boltz.

The details

BoltzMol-1 can be configured to consider only small molecules that can be made from a limited set of available compounds, which narrows the search to candidates a chemistry lab can actually synthesize. BoltzProt-1 generates protein designs and then automatically reviews each one to judge whether it could be used to develop a new drug. Customers access both algorithms through an application programming interface billed by token usage, a pay-per-computation model common to AI software.

Timeline

  1. June: BoltzMol-1 and BoltzProt-1 launched.

  2. Wednesday: Boltz announced the $110 million Series A funding round.

The Tech Race

Boltz is positioning its molecule and protein design models as commercial infrastructure for drug discovery, a field where AI labs are also competing for the same pharmaceutical customers. The Series A is intended to fund more headcount and computing hardware so the company can keep pace with leading AI labs.

Pharmaceutical researchers can access BoltzMol-1 and BoltzProt-1 through an API billed by token usage, and six of the 20 largest drugmakers already use the company's tools. The source does not state broader availability, pricing tiers, or a timeline for wider access.

The takeaway

AI tools for drug design are moving from research demos to paid infrastructure that pharmaceutical companies buy by usage. Watch whether Boltz publishes independent benchmarks for its hit rates in the coming months, since customer growth alone does not confirm the models' scientific performance.

Further reading

For more on the companies building this kind of tooling, see our coverage of Startups.

Live Poll

Do you think AI will make new medicines faster and cheaper for ordinary people?